Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Aug 4;12(8):e01776.
doi: 10.14309/crj.0000000000001776. eCollection 2025 Aug.

Semaglutide-Induced Liver Injury

Harsimran Kalsi  1 , Samneet Singh Arora  2 , Kobina Essilfie-Quaye  1 , Raghav Bassi  3 , Neeka Akhavan  4 , Yaseen Perbtani  1   5 , Tony S Brar  1   5
Affiliations
Case Reports

Semaglutide-Induced Liver Injury

Harsimran Kalsi et al. ACG Case Rep J. .

Abstract

Semaglutide, a glucagon-like peptide-1 receptor agonist widely used for managing type 2 diabetes mellitus and obesity. Reports of semaglutide-associated hepatotoxicity are exceedingly rare. We detail a case of a 44-year-old woman who developed liver injury with elevated liver enzymes after semaglutide initiation for weight management. Liver enzyme levels normalized after discontinuing the drug and worsened upon rechallenge, confirming semaglutide's potential to cause liver injury. In addition, our case study encompasses a literature review of all reported semaglutide-related drug-induced liver injury cases, highlighting the need for diligent liver function monitoring in patients on semaglutide and offering valuable insights into its hepatotoxic potential.

Keywords: GLP-1 receptor agonists; drug-induced liver injury; hepatotoxicity; semaglutide.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The temporal relationship between semaglutide administration and liver enzymes alanine transaminase and aspartate transaminase patterns. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DILI, drug-induced liver injury.
See this image and copyright information in PMC

References

    1. Mahapatra MK, Karuppasamy M, Sahoo BM, Karuppasamy M, Mohan Sahoo B, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review. Pharm Res. 2022;39(6):1233–48. - PMC - PubMed
    1. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):73–80. - PMC - PubMed
    1. Ma J, Mathur K, Muldoon J, Ghabril M, Chalasani N, Vuppalanchi R. Progressive cholestasis and biliary cirrhosis after initiating oral semaglutide: Report from the drug-induced liver injury network. ACG Case Rep J. 2022;9(12):e00922. - PMC - PubMed
    1. Yin D, Ding LL, Zhou HR, Qiu M, Duan XY, Duan XY. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: A meta-analysis of the SUSTAIN and PIONEER trials. Endocr J. 2021;68(6):739–42. - PubMed
    1. Danan G, Teschke R, Rolf T, Teschke R. Roussel Uclaf causality assessment method for drug-induced liver injury: Present and future. Front Pharmacol. 2019;10:853. - PMC - PubMed

Publication types

LinkOut - more resources